Dr Richard Shaffer specialises in using chemotherapy and radiotherapy to treat brain tumours, prostate and bladder cancer, and skin cancer. He has extensive experience of using highly technical radiotherapy, including Intensity Modulated Radiation Therapy (IMRT) for prostate cancer and brain tumours. He is able to offer IGRT (image-guided radiotherapy) for prostate cancer. He is currently developing a local intracranial stereotactic radiotherapy service.
He is at the forefront of the treatment of early Dupuytren’s disease of the hand (and Ledderhose disease of the feet) with radiotherapy following the NICE guidelines in November 2010, and acts as a medical advisor to the British Dupuytren’s Society.
Dr Shaffer has been involved in a number of research projects including planning studies comparing conventional IMRT with volumetric modulated arc therapy (VMAT) and RapidArc in several disease sites such as prostate, breast, high-grade glioma, and paediatric tumours, and has presented and been published widely in the oncology arena.
He is currently the chair of the IMRT-IGRT Radiotherapy Group, chairs the Network Brain Tumour Working Group, and is an active member of the St Lukes Radiotherapy Strategy Group. He is a member of the NCRI Brain Tumour Clinical Studies Group. He is also a trustee of the Fountain Centre, a charity which provides information, support, counselling and complementary therapies for cancer patients and their carers and relatives at St Lukes Cancer Centre.
Previous to his role at the Royal Surrey County Hospital, Dr Shaffer completed a Clinical Fellowship in Radiation Oncology at the British Columbia Cancer Agency in Vancouver, Canada. He gained further skills in specialist registrar posts at Charing Cross Hospital, Royal Free Hospital and University College London Hospital.
Radiotherapy for Dupuytren’s disease.
Radiotherapy for benign disease.
Current NHS post
Royal Surrey County Hospital.
Royal College of Radiologists.
Visit The Dupuytrens Practice for more information regarding the treatment of Dupuytren’s disease using radiotherapy.